Perampanel is an antiepileptic drug that is approved for treatment of focal and generalised tonic–clonic seizures in patients aged ≥12 years.
Our PK analysis demonstrates that pharmacokinetics of perampanel are similar in adolescents to adults.
A recent Phase II study in adolescents demonstrated no overall impact on cognition compared with placebo, during a 19-week double-blind clinical trial.
Our PK/PD analysis show no relationship between perampanel exposure and cognitive function, which suggests a benign cognitive profile for this AED in adolescents.